arrow
A

Alberto López-García

hospital spedali civili brescia
H指数:17
被引数:1,294

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report
2024-12-230
OAAI
Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation in a Spanish Multicenter Cohort on Behalf of Geth

异基因造血细胞移植中移植预处理强度(TCI)评分在西班牙多中心队列中的验证(代表Geth)

BLOOD
IF23.1
2024-11-050
PRE
Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

西班牙套细胞淋巴瘤(MCL)治疗模式与治疗顺序的演变及其对生存的影响:Geltamo-MCL-2022研究

BLOOD
IF23.1
2024-11-050
PRE
Cardiac events after allo-HCT in patients with acute myeloid leukemia
2024-10-240
PRE
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

慢性淋巴细胞白血病患者的治疗策略和治疗顺序: 欧洲CLL研究计划ERIC的国际研究

2024-09-170
OAAI
Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes
2024-07-112
OAAI
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey (vol 52, pg 1125, 2024)

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查结果 (第52卷,1125页,2024页)

2024-05-210
OAAI
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022
2024-05-015
OAAI
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

地塞米松治疗新型冠状病毒肺炎与血液系统恶性肿瘤患者的死亡率增加有关: EPICOVIDEHA注册表的结果

2024-04-042
OAAI
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查的结果

2024-02-224
OAAI
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry

通过新型冠状病毒肺炎大流行,多发性骨髓瘤和SARS-COV-2感染的生存率: epicovideha注册表的结果

2023-12-049
OAAI
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

CLL历史上的其他恶性肿瘤: ERIC进行的一项国际多中心研究,欧洲CLL研究倡议,和谐

2023-11-016
OAAI
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

慢性淋巴细胞白血病患者新型冠状病毒肺炎和COVID后病情的演变: 欧洲CLL研究计划ERIC的一项研究

2023-09-2911
OAAI
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
2023-06-1316
OAAI
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

tixagevimab/cilgavimab对血液系统恶性肿瘤和新型冠状病毒肺炎患者的被动暴露前预防接种: EPICOVIDEHA注册表中的配对分析

2023-04-0113
OAAI
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

新型冠状病毒肺炎血液系统恶性肿瘤患者的尼马曲韦/利托那韦: EPICOVIDEHA登记处的报告

2023-04-0123
OAAI